Media headlines about Enzo Biochem (NYSE:ENZ) have trended somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.5944225014994 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Separately, TheStreet lowered Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th.

Shares of Enzo Biochem (NYSE ENZ) opened at $7.63 on Friday. The firm has a market capitalization of $376.34, a P/E ratio of -254.33 and a beta of 0.87. Enzo Biochem has a 1 year low of $6.27 and a 1 year high of $12.04.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings data on Thursday, December 7th. The medical research company reported ($0.01) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.01). The firm had revenue of $27.68 million for the quarter, compared to analyst estimates of $27.51 million. Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. equities analysts expect that Enzo Biochem will post -0.02 EPS for the current year.

In other news, CEO Elazar Rabbani sold 72,401 shares of Enzo Biochem stock in a transaction that occurred on Wednesday, October 25th. The stock was sold at an average price of $10.09, for a total value of $730,526.09. Following the sale, the chief executive officer now directly owns 2,038,474 shares in the company, valued at approximately $20,568,202.66. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP James Michael O’brien sold 22,866 shares of Enzo Biochem stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $10.28, for a total value of $235,062.48. Following the completion of the sale, the executive vice president now owns 34,886 shares in the company, valued at $358,628.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 191,398 shares of company stock worth $1,925,292. Corporate insiders own 8.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/13/enzo-biochem-enz-receives-news-sentiment-rating-of-0-16.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Insider Buying and Selling by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.